Genome-wide analysis identifies novel susceptibility loci for myocardial infarction.

Journal Article (Journal Article)

AIMS: While most patients with myocardial infarction (MI) have underlying coronary atherosclerosis, not all patients with coronary artery disease (CAD) develop MI. We sought to address the hypothesis that some of the genetic factors which establish atherosclerosis may be distinct from those that predispose to vulnerable plaques and thrombus formation. METHODS AND RESULTS: We carried out a genome-wide association study for MI in the UK Biobank (n∼472 000), followed by a meta-analysis with summary statistics from the CARDIoGRAMplusC4D Consortium (n∼167 000). Multiple independent replication analyses and functional approaches were used to prioritize loci and evaluate positional candidate genes. Eight novel regions were identified for MI at the genome wide significance level, of which effect sizes at six loci were more robust for MI than for CAD without the presence of MI. Confirmatory evidence for association of a locus on chromosome 1p21.3 harbouring choline-like transporter 3 (SLC44A3) with MI in the context of CAD, but not with coronary atherosclerosis itself, was obtained in Biobank Japan (n∼165 000) and 16 independent angiography-based cohorts (n∼27 000). Follow-up analyses did not reveal association of the SLC44A3 locus with CAD risk factors, biomarkers of coagulation, other thrombotic diseases, or plasma levels of a broad array of metabolites, including choline, trimethylamine N-oxide, and betaine. However, aortic expression of SLC44A3 was increased in carriers of the MI risk allele at chromosome 1p21.3, increased in ischaemic (vs. non-diseased) coronary arteries, up-regulated in human aortic endothelial cells treated with interleukin-1β (vs. vehicle), and associated with smooth muscle cell migration in vitro. CONCLUSIONS: A large-scale analysis comprising ∼831 000 subjects revealed novel genetic determinants of MI and implicated SLC44A3 in the pathophysiology of vulnerable plaques.

Full Text

Duke Authors

Cited Authors

  • Hartiala, JA; Han, Y; Jia, Q; Hilser, JR; Huang, P; Gukasyan, J; Schwartzman, WS; Cai, Z; Biswas, S; Trégouët, D-A; Smith, NL; INVENT Consortium, ; CHARGE Consortium Hemostasis Working Group, ; GENIUS-CHD Consortium, ; Seldin, M; Pan, C; Mehrabian, M; Lusis, AJ; Bazeley, P; Sun, YV; Liu, C; Quyyumi, AA; Scholz, M; Thiery, J; Delgado, GE; Kleber, ME; März, W; Howe, LJ; Asselbergs, FW; van Vugt, M; Vlachojannis, GJ; Patel, RS; Lyytikäinen, L-P; Kähönen, M; Lehtimäki, T; Nieminen, TVM; Kuukasjärvi, P; Laurikka, JO; Chang, X; Heng, C-K; Jiang, R; Kraus, WE; Hauser, ER; Ferguson, JF; Reilly, MP; Ito, K; Koyama, S; Kamatani, Y; Komuro, I; Biobank Japan, ; Stolze, LK; Romanoski, CE; Khan, MD; Turner, AW; Miller, CL; Aherrahrou, R; Civelek, M; Ma, L; Björkegren, JLM; Kumar, SR; Tang, WHW; Hazen, SL; Allayee, H

Published Date

  • March 1, 2021

Published In

Volume / Issue

  • 42 / 9

Start / End Page

  • 919 - 933

PubMed ID

  • 33532862

Pubmed Central ID

  • PMC7936531

Electronic International Standard Serial Number (EISSN)

  • 1522-9645

Digital Object Identifier (DOI)

  • 10.1093/eurheartj/ehaa1040

Language

  • eng

Conference Location

  • England